Viravaxx provides novelties in hard-to-treat viral infections, such as respiratory syncytial virus (RSV) and rhinovirus (RV), which have resisted vaccination approaches for a long time. To this end, Viravaxx collaborates with the Valenta Labs at the Medical University of Vienna. The Valenta labs exploit technology to convert non-immunogenic epitopes of surface proteins essential for the virus life cycle to potent immunogens. In addition, the Valenta labs develop multiplexed tools for high resolution serum immune diagnostics.
The Valenta Labs and Viravaxx recently developed a test to determine SARS-CoV-2 Protective Antibodies: